MOTS-c

Clinical Summary

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid mitochondrial-derived peptide discovered in 2015 by Lee et al. at the USC Leonard Davis School of Gerontology (PMID: 25738459). Encoded by mitochondrial DNA rather than nuclear DNA, it represents a novel class of retrograde signaling molecules (mitochondria-to-nucleus). 100% sequence-conserved across mammals (human, mouse, rat, monkey: MRWQEMGYIFYPRKLR).

Who benefits most (theoretical): Individuals with insulin resistance, age-related physical decline, or metabolic dysfunction who want to augment exercise adaptation. Animal models consistently show improved glucose metabolism, exercise performance, and cardiac protection across 90+ studies.

The honest reality: Despite 90+ animal studies and genuinely interesting biology, no completed human dosing trial exists. A landmark development occurred in February 2026: Hudson Biotech began recruiting for NCT07505745, a Phase 2a randomized placebo-controlled trial of exogenous native MOTS-c (SubQ) in 120 adults with prediabetes and overweight/obesity. Primary endpoints are insulin sensitivity (Matsuda Index) and safety (TEAEs). Results expected ~2028. Until those results arrive, every dosing protocol in circulation remains allometric scaling from mouse IP injection. The published "human studies" (10+) only measured endogenous MOTS-c levels — none administered exogenous MOTS-c and reported results.

Why the gap is narrowing: CohBar Inc. completed a Phase 1a/1b trial of CB4211 (a MOTS-c analog) for NAFLD (NCT03998514) with positive topline results (well-tolerated, no SAEs, significant ALT/AST reductions, glucose decreases) before pivoting away from development. The CK2 direct binding discovery (2024, PMID: 39559755) provided the first clear molecular target. Hudson Biotech's Phase 2a trial represents the first attempt to validate native MOTS-c in humans.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No FAERS signals (zero FAERS reports exist for MOTS-c — compound is outside FDA pharmacovigilance) | MON Monitor | WARN FAERS signal | AVOID Contraindicated

5/5 Multiple large RCTs + MA | 4/5 Several human RCTs | 3/5 Some human pilot data | 2/5 Animal only | 1/5 No evidence / conflicting / single study

Critical note: Every indication is rated 2/5 or lower. The first human interventional trial (NCT07505745) is recruiting but has no results. All -- Safety Flags reflect zero FAERS reports — this is because MOTS-c has never been an FDA-approved drug, not because safety has been established. Published human studies are ALL observational (endogenous levels only):

1. von Walden et al. (2021) PMID: 34351816 — 45 min cycling increased circulating MOTS-c ~40% in 10 healthy humans.
2. Dieli-Conwright et al. (2021) PMID: 34413391 — 16-week exercise increased MOTS-c in breast cancer survivors (N=82).
3. Yoon et al. (2026) PMID: 41551324 — MOTS-c INCREASED in obese adults, contradicting "deficiency" narrative.
4. Luo et al. (2025) PMID: 40538389 — Reduced serum MOTS-c in obstructive sleep apnea patients.
5. Rodríguez-Esparragón et al. (2025) PMID: 41303353 — MOTS-c/humanin as Alzheimer's biomarker with telomere length.
6. Kutuk et al. (2026) PMID: 41680431 — Reduced MOTS-c in PCOS women + mitochondrial dysfunction.
7. Ozkaya et al. (2025) PMID: 41004666 — MOTS-c in obesity with inflammation, IR, endothelial dysfunction.
8. Cao P et al. (2025) PMID: 41368821 — Circulating MOTS-c HIGHER in acute coronary syndrome; prognostic biomarker for MACE in AMI (N=200+).
9. Kim S (2024) PMID: 39457696 — K14Q polymorphism associated with sarcopenia, blood lipids, and mental health in 200+ older Korean adults. First population-level pharmacogenomic study.
10. Iboleón-Jiménez A et al. (2025) PMID: 40443515 — Circulating mitochondrial biomarkers (incl. MOTS-c) in acute coronary syndrome.
11. Coskun et al. (2024) PMID: 39704971 — Altered MOTS-c levels in untreated preeclampsia patients.
12. Additional: heat stress (40674654), PCOS polymorphism (41945630), sarcopenia/dialysis (40005438), hemodialysis CVD (39111290), SGLT2i effects (39182552), CPB surgery (40035775), breast cancer/metformin (36490309), adrenal tumors (39201408), MI biomarker (40353474), aortic valve (40104672), T1D kidney (39711006), multiple myeloma (41479490).

Prescribing

Dosing

Every dose below is allometric scaling from mouse IP injection. NCT07505745 (Phase 2a) will provide the first human dosing data — results expected ~2028.

Allometric conversion formula: HED (mg/kg) = Mouse dose (mg/kg) x (Mouse Km 3 / Human Km 37) = x 0.081. Mice received IP injection; human protocols assume SubQ. Route conversion adds further uncertainty.

If someone insists on using this compound, a conservative titration: Week 1-2: 5 mg every other day (assess tolerance). Week 3-4: 5 mg daily. Week 5+: adjust 5-15 mg daily based on response. Minimum effective dose is unknown. Monitor fasting glucose closely if diabetic or on glucose-lowering medications — reduce diabetes med doses by 10-20% proactively.

Formulations

Route ranking: SubQ > IM > IV (medical setting only) > Nasal (no data) > Oral (not viable). Nasal sprays are being marketed but have zero bioavailability or efficacy data for MOTS-c specifically.

Stability warning: MOTS-c degrades faster than most peptides — ~25% activity loss after 24 hours at room temperature. Reconstitute and refrigerate immediately. Many negative user reports may stem from degraded product.

Pharmacokinetics (ALL ESTIMATED — no human PK study exists; NCT07505745 includes immunogenicity endpoints but likely not full PK):

• Tmax: 30-90 min (SubQ, estimated)
• Half-life: 4-6 hours (estimated)
• Clearance: Renal (inferred from peptide size, 2.17 kDa)
• Metabolism: Proteolytic degradation by peptidases
• Peak plasma, Cmax, AUC, protein binding: ALL UNKNOWN

Safety

Interactions

All interaction evidence is 1/5 Theoretical except metformin (2/5 mechanistic) and SGLT2i (1/5 + 1 observational). Zero drug interaction studies have been conducted.

Unknown interactions (no data): Other peptides (BPC-157, TB-500), GH/IGF-1, SARMs, adaptogens, nootropics

Contraindications

Absolute:

• Pregnancy and lactation — zero safety data; MOTS-c protects against placental injury in IUGR mice (PMID: 41268602) but this is not evidence for human gestational use
• Active cancer — AMPK effects on tumors are complex and tumor-type specific; anti-tumor in ovarian/HCC (PMIDs: 39321430, 39581216), but pro-survival possible in other types; avoid without oncologist approval
• Severe renal failure (GFR <15) — renally cleared, accumulation risk
• Known peptide hypersensitivity

Relative (use with extreme caution):

• Moderate renal impairment (GFR 30-60) — reduce dose 25-50%
• Hypoglycemia-prone individuals or those on insulin/sulfonylureas
• Pediatric (<18) — zero data
• Planned surgery within 2 weeks — unknown effects on healing

Adverse Effects

Published human data: NONE from completed exogenous dosing trials. NCT07505745 will collect TEAE data through week 16.

CB4211 analog (NCT03998514, completed): Well-tolerated in 88 subjects (20 in NAFLD arm), no SAEs reported, ALT -25%/AST -17% vs placebo, glucose decreases. However, liver fat (MRI-PDFF) was not different from placebo — the primary hepatic endpoint did not meet significance. Persistent injection site reactions noted. CohBar AASLD 2021 late-breaker. CB4211 is an analog, not native MOTS-c — transferability uncertain.

Animal data (up to 18 months chronic dosing in mice): No serious adverse effects, no organ toxicity, no increased mortality. Wide therapeutic index (10-100x doses tolerated). The Sports Med review (Mendias & Awan, 2026, PMID: 41966639) classifies MOTS-c as having "insufficient human safety/efficacy data" — this is an evidence gap, not a safety signal.

Community-reported adverse effects (anecdotal — see Community section):

• Injection site pain/burning — near-universal, described as notably worse than other peptides; likely mast cell activation
• Mast cell response: flushing, redness, itching, mild hives post-injection
• Heart palpitations / increased heart rate — flagged by USADA as reported among online purchasers
• Insomnia — if injected too late in day
• Transient fatigue (first 1-2 weeks)
• GI distress (minority)
• Hypoglycemia (if combined with glucose-lowering medications)

Theoretical concerns:

• Immunogenicity (antibody formation — NCT07505745 includes anti-drug antibody endpoint)
• Long-term effects of chronic exogenous MOTS-c — zero data
• Possible downregulation of endogenous production — not studied

Product quality risk (CRITICAL): Most MOTS-c is from unregulated research peptide suppliers. Studies show 30% of internet-purchased research peptides contain incorrect amino acid sequences and 65% exceed safety thresholds for endotoxin contamination. U.S. peptide imports from China nearly doubled in 2025 ($328M in first 9 months); customs seizures sharply increasing (151 in Q1 2025 vs 132 in all FY2024). Demand CoA with HPLC purity >98%, mass spectrometry (MW 2174.5 Da), endotoxin testing (<1.0 EU/mg), sterility confirmation. "99% Pure" labels are unreliable. Discard if cloudy or discolored. MOTS-c degrades ~25% in 24h at room temp — cold chain critical.

FAERS Signal Table

Reading FAERS data: Zero FAERS reports exist because MOTS-c has never been an FDA-approved or marketed drug product. This does NOT indicate safety — it indicates the compound is entirely outside the formal pharmacovigilance system. Adverse events from gray-market research peptide use are not captured by FAERS.

Monitoring

Stop immediately if: hypoglycemia symptoms, creatinine rise >0.5 from baseline, ALT/AST >2x ULN, allergic reaction, persistent palpitations, infection signs at injection site.

Synergies & Stacking

The strongest synergy is exercise. Multiple animal studies confirm additive/synergistic benefits. Exercise also naturally increases endogenous MOTS-c ~40% (PMID: 34351816) and promotes MOTS-c secretion from skeletal muscle (PMID: 39706498). This raises the question: if you're already exercising (which you should be), how much additional benefit does exogenous MOTS-c provide? Unknown.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Cautiously positive across ~100-150 substantive reports (growing). Users treat MOTS-c as a subtle metabolic optimizer, not a dramatic game-changer. Those expecting acute effects ("a rush") are typically disappointed. Community described the effect as "a mellow, constant and clean energy stream" (GLP-1 Forum). MESO-Rx users increasingly converging on LOWER doses (1-3 mg daily) than previously popular (5 mg 3x/week).

What Users Report

Community Dosing vs Clinical

All human doses are speculative. The wide range (1-15 mg, daily to 3x/week) reflects complete absence of dose-finding data. 2026 trend: community converging on lower doses (1-3 mg) than earlier protocols (5-10 mg).

Popular Stacks (Community)

Red Flags & Skepticism Notes

• Influencer concentration: Jay Campbell (jaycampbell.com) dominates MOTS-c dosing protocol conversation. He sells peptide books and coaching — clear commercial interest. Not MLM, but not independent.
• Content-farm ecosystem (expanding rapidly): PeptideFox, PeptideDeck, SeekPeptides, PeptideDosages.com, PeptideDossier.com, PeptidesInsider.com, PeptideProtocolWiki.com, ThePeptideGuides.com, ThePeptideCatalog.com — all near-identical SEO content with vendor affiliate links. Ring growing since 2025.
• Astroturfing signals: AI-generated content prevalence increasing across vendor/info sites (identical structure, same talking points, same disclaimers). "Research only" disclaimers used as legal shields while marketing therapeutic use.
• TikTok emergence: MOTS-c content appearing on TikTok (e.g., @itsari_b posting about MOTS-C + GLP-1 stacking). New platform for peptide marketing.
• CNN investigation (Nov 2025): "The trend of unproven peptides is spreading through influencers and RFK Jr. allies" — MOTS-c sits within this broader ecosystem.
• Practitioner training: Clinics offering MOTS-c typically completed "Peptide Therapy Training" (often from Dr. Seeds' programs). No published case series or outcomes data — only marketing copy. Notable exception: Adjust Clinic published a "Separating Science from Hype" analysis acknowledging the evidence gap.
• No MLM structure identified for MOTS-c specifically.
• Stability as scapegoat: MOTS-c degrades ~25% in 24h at room temp. This creates a convenient excuse for vendors when product doesn't work.
• Quality crisis: Studies show 30% of internet-purchased research peptides contained incorrect amino acid sequences; 65% exceeded safety thresholds for endotoxin contamination. "99% Pure" labels are unreliable.

Folk vs Clinical Reality Check

Community experience aligns with animal data in direction (energy, metabolic improvement, endurance) but the magnitude of reported effects is highly variable. The near-universal injection site pain is a genuine signal not well-represented in animal literature (mice don't report pain scores); the community discovery that initial doses sting more than later doses suggests mast cell desensitization. The palpitations/tachycardia reports are concerning and have no animal precedent — this could be a mast cell activation phenomenon, a real cardiac effect, or nocebo. The disconnect between dramatic fat-loss testimonials and the majority of "subtle/nothing" reports suggests strong responder/non-responder variability, product quality issues (30% incorrect sequences in grey-market peptides), or publication bias in anecdotes. The 2026 dose de-escalation trend on MESO-Rx (1-3 mg vs 5-10 mg) may indicate the community is self-correcting toward more appropriate doses.

Negative findings: No community signal for cognitive/mood/hair/skin/libido effects despite theoretical mechanisms. MOTS-c biohacker adoption remains almost entirely Western (primarily US). East Asian communities contribute research but do NOT self-experiment.

Deep Dive: Mechanisms & Research

Key Mechanisms (With Clinical Translation)

1. Folate-AICAR-AMPK Pathway — MOTS-c disrupts the folate-methionine cycle, accumulating AICAR, which activates AMPK (Thr172 phosphorylation). Downstream: GLUT4 translocation (glucose uptake), ACC inhibition (fatty acid oxidation), PGC-1alpha upregulation (mitochondrial biogenesis), hepatic gluconeogenesis suppression (PEPCK/G6Pase down). Confirmed in HFD mice with 40% glucose tolerance improvement (PMID: 25738459). Gudiksen et al. (2026, PMID: 41520850) showed MOTS-c directly improves intrinsic muscle mitochondrial bioenergetic efficiency via PGC-1alpha/AMPK. Clinical translation: Core mechanism behind all metabolic claims. NCT07505745 tests this directly (Matsuda Index primary endpoint).

2. Nuclear Translocation Under Stress — Under glucose restriction or oxidative stress, MOTS-c translocates from cytoplasm to nucleus (~3-fold increase), binds chromatin, and regulates antioxidant genes (Nrf2 pathway), metabolic adaptation genes, and stress response genes (PMID: 29983246). Li et al. (2025, PMID: 40403491) identified MYH9 (myosin heavy chain 9) as essential mediator of nuclear entry. Nrf2 activation now demonstrated across lung (BPD: 41802484; radiation: 38790718), placenta (IUGR: 41268602), and cartilage (OA: 41043625). Clinical translation: Most distinctive feature — a mitochondrial peptide regulating nuclear gene expression. Paradigm-shifting biology. Zero human validation.

3. CK2 Direct Binding (2024) — Kumagai et al. identified casein kinase 2 as a direct molecular target. CK2 activation leads to PTEN inhibition, PI3K-AKT enhancement, mTORC2 activation, insulin sensitivity, and reduced myostatin. K14Q natural variant shows ~40% reduced CK2 binding (PMID: 39559755). Clinical translation: First clear molecular target for drug development.

4. Anti-Inflammatory Cascade — PPARgamma activation suppresses NF-kappaB signaling, reducing TNF-alpha, IL-6, IL-1beta while increasing IL-10. Nrf2 pathway upregulates antioxidant enzymes (SOD, catalase, GPx). Demonstrated across cardiac, pulmonary, and metabolic disease models. ROS/TXNIP/NLRP3 inflammasome pathway in diabetic cardiomyopathy (PMID: 39616938). Clinical translation: Consistent across models, suggesting a real pathway.

5. Emerging Mechanisms (2024-2026):

• SLC7A11/ferroptosis suppression in spermatogenesis (PMID: 41933740)
• FPR2-mediated ferroptosis in acute lung injury (PMID: 38527401)
• MAPK signaling in liver protection independent of AMPK (PMID: 41764620)
• Keap1-Nrf2-Smad2/3 in diabetic liver fibrosis (PMID: 40425777)
• Bcl-2 interaction in NASH (PMID: 38206815)
• MEF2A activation overcoming HCC TRAIL resistance (PMID: 39581216)
• TRIM72-mediated plasma membrane repair (PMID: 39267782)
• Interferon-responsive host defense/antimicrobial (PMID: 39553971)
• BH4/BDNF pathway in autism model (PMID: 41706383)
• THBS1/TGF-beta inhibition in diabetic myocardial fibrosis (PMID: 41710402)
• Mitophagy promotion under high-altitude hypoxia (PMID: 41654147)
• AMPK-HIF-1alpha-PFKFB3 glycolysis in CPB lung injury (PMID: 40035775)
• Adrenal cortex metabolic priming without steroidogenesis (PMID: 41811086)
• Nrf2 in BPD neonatal lung protection (PMID: 41802484)
• Nrf2 in placental protection during IUGR (PMID: 41268602)
• Nrf2 in OA pyroptosis/cartilage degradation (PMID: 41043625)
• Nrf2 in allergic asthma airway barrier via epithelial apoptosis inhibition (PMID: 40472776)
• Dose-dependent effects in AMD retinal cells/cybrids (PMID: 39961901)
• DNA-PKcs disrupts MOTS-c/JNK pathway in septic myocardial microvascular injury (PMID: 38389837)
• Central (ICV) MOTS-c infusion modulates FSH/LH/testosterone differentially in obese vs lean rats (PMID: 38462167)
• Muscle fiber type-specific effects on differentiation and metabolism (PMID: 39876762)
• Protection against cyclophosphamide-induced reproductive damage with humanin (PMID: 39079574)
• Central + peripheral analgesic mechanisms in inflammatory pain model (PMID: 37899006)
• Hindlimb suspension muscle disuse — MOTS-c preserves soleus function (PMID: 40608240)
• Exercise intensity modulates MOTS-c in diabetic sand rats (PMID: 38636847)
• Avian MOTS-c characterized as metabolic regulator — cross-species conservation beyond mammals (PMID: 40805020)

Clinical translation: These expand MOTS-c biology into ferroptosis, innate immunity, membrane repair, neurodevelopment, fibrosis, and joint protection. All pre-clinical. The breadth suggests MOTS-c is a fundamental stress-response peptide rather than a single-indication drug.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

NCT07505745 is the landmark trial: First-ever interventional study of native MOTS-c peptide in humans. Randomized, placebo-controlled, SubQ injection, 12 weeks. Primary endpoints: Matsuda Index (insulin sensitivity) + TEAEs. Secondary: HbA1c, fasting glucose, 2h glucose, immunogenicity (anti-drug antibodies). Sponsor: Hudson Biotech. Site: Peking University Shenzhen Hospital, China. Results expected ~2028.

NCT03998514 (CB4211): Completed with mixed topline results (AASLD 2021 late-breaker): well-tolerated in 88 subjects, no SAEs, ALT -25%/AST -17% vs placebo, glucose decreases, weight trend. But liver fat (MRI-PDFF) not different from placebo — the primary hepatic endpoint did not meet significance. Persistent injection site reactions noted. CB4211 is a MOTS-c analog, not native peptide — results are suggestive but not directly transferable. CohBar pivoted away; no further development.

No East Asian registry trials (JPRN, CRiS, ChiCTR) found. No medical society guidelines mention MOTS-c. No Cochrane reviews. No head-to-head comparisons.

Regulatory Status

• FDA: No approval. No NDA filed. Not in Drugs@FDA. No OpenFDA safety data. MOTS-c was placed on FDA 503A Category 2 list (Sept 2024) as a bulk drug substance posing "significant safety risks" — compounding pharmacies were prohibited from compounding MOTS-c for human use. Category 1 reclassification announced by HHS Secretary RFK Jr. on Feb 27, 2026 (covering ~14 of 19 Category 2 peptides including MOTS-c), but formal Federal Register publication has NOT occurred as of April 2026 — legal status technically unchanged until published. Note: FDA ended the Category 1/2/3 system in Jan 2025, but the prohibition on compounding MOTS-c persists under the new framework until the reclassification is formally published. Category 1 would allow compounding pharmacy preparation with physician Rx; it does NOT mean FDA approval.
• EMA: No data. Not submitted.
• WADA: Prohibited at all times under S4.4.1 (Metabolic Modulators — AMPK activators). Confirmed 2025 and 2026 Prohibited Lists. Athletes subject to testing must not use.
• TGA (Australia): Not on ARTG. Subject to tightened 2026 peptide import regulations.
• Regulatory context: No pharma company has an active program for native MOTS-c. The patent barrier (endogenous 16-aa peptide), unclear indication pathway, and pre-clinical stage make commercial investment unattractive. This is a structural economics problem, not suppression.

Genetic Polymorphism: m.1382A>C

The m.1382A>C polymorphism (K14Q variant) in the MOTS-c coding region is enriched in Japanese centenarians (PMID: 26289118). Q14 variant shows ~40% reduced CK2 binding. Investigated in PCOS (PMID: 41945630). Association data only — population-specific (East Asian).

Endogenous MOTS-c Biology

Endogenous expression: highest in skeletal muscle, also heart, liver, adipose, brain, vascular endothelium, adrenal cortex (PMID: 41811086). Plasma levels decline with age, lower in insulin-resistant individuals, increase ~40% with acute endurance exercise (PMID: 34351816), and endurance training promotes MOTS-c secretion from muscle (PMID: 39706498).

Obesity paradox (2024-2026): Meta-analysis (PMID: 39160573) found MOTS-c significantly reduced in T2DM (SMD = -0.89) but INCREASED in obesity (SMD = +0.51). Yoon et al. (PMID: 41551324) confirmed MOTS-c INCREASED in obese adults and remained unchanged after weight loss. Ozkaya et al. (PMID: 41004666) found MOTS-c associated with inflammation and endothelial dysfunction in obesity. The simple "deficiency replacement" narrative is likely wrong — the relationship involves compensatory upregulation, not depletion. No clinical diagnostic cutoffs or standardized assays exist.

Comparison with Other Mitochondrial-Derived Peptides

MOTS-c is the first MDP to reach a human interventional trial for native peptide. Humanin leads in neuroprotection research.

Ataraxia Verdict (as of 2026-04-14)

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale below.

Hype Check (Mode 1: Fallacy Radar)

Overblown claims:

• "Clinically proven metabolic enhancer" — no completed human dosing trial. NCT07505745 is recruiting but has zero results. Every mouse study used IP injection, not SubQ.
• Detailed human injection protocols with specific doses, timing, titration schedules — for a compound with no human dose-finding data. The entire dosing section of every MOTS-c guide is speculative.
• "Exercise in a bottle" — exercise increases endogenous MOTS-c by 40% through the intended physiological pathway. If you exercise, you're already activating this system.
• "Human studies prove it works" — equivocation fallacy. Published "human studies" measured endogenous levels, not exogenous dosing. The word "study" does not mean "they gave it to people."
• The 2026 obesity paradox (PMID: 41551324): MOTS-c was HIGHER in obese adults, undermining the "deficiency replacement" narrative.

Legitimately interesting (in animals):

• Insulin sensitivity via AMPK — consistent across multiple labs and models; NCT07505745 tests this
• Late-life physical decline prevention — Reynolds 2021 Nature Comms is genuinely impressive
• Cardiac protection — replicated across TAC, diabetic cardiomyopathy, I/R, high-altitude, and fibrosis models
• Nuclear translocation — paradigm-shifting biology for mitochondrial signaling
• CK2 direct binding — first clear molecular target for MDP drug development
• Research velocity tripling (2024-2026) with expansion into AMD, OA, autism, sleep apnea, disc degeneration, BPD
• CB4211 analog completed Phase 1 with positive topline results — proof of concept for the class

Evidence Gaps

• No completed human dosing trial — NCT07505745 recruiting; results ~2028
• No human pharmacokinetics — Tmax, Cmax, AUC, half-life ALL estimated
• No human safety data — NCT07505745 will provide first TEAE data; CB4211 analog was well-tolerated but is different compound
• Route mismatch — all animal studies used IP injection; human protocols assume SubQ equivalence
• Obesity paradox — meta-analysis shows MOTS-c UP in obesity, DOWN in T2DM; the deficiency narrative is oversimplified
• Exercise confounder — whether exogenous MOTS-c adds benefit beyond exercise alone is completely unknown
• Immunogenicity — will MOTS-c trigger antibody formation? NCT07505745 includes this endpoint
• Endogenous downregulation — whether exogenous dosing suppresses your own MOTS-c production is unstudied

Bias Flags (Mode 4: First Principles)

• Evidence quality inflation: Prior version rated evidence as "moderate-strong." It is preliminary. Animal-only data cannot be rated higher than preliminary regardless of consistency.
• Cui bono: Peptide suppliers profit ($140-250/vial × monthly). No pharma opposition — compound too early-stage. Not suppression; pre-clinical science marketed as validated therapeutics.
• Exercise confounder: Observational data showing exercise increases MOTS-c is used to market exogenous MOTS-c. First principles says: exercise IS the intervention, injection is the unvalidated one.
• Publication bias: 90+ animal studies, overwhelmingly positive. Either genuinely robust in mice, or negative results are unpublished. Probably both.
• Regulatory ≠ validation: WADA prohibition and FDA Category 1 reclassification are regulatory categories, not evidence assessments. FDA reclassification was policy-driven (Kennedy HHS), not evidence-driven.
• Assumption challenge — "more MOTS-c = better": PMID 41551324 shows MOTS-c is HIGHER in obesity. The dose-response relationship in humans is unknown. Supraphysiological dosing might not be beneficial.
• Assumption challenge — "exogenous = endogenous": SubQ injection delivering peptide to plasma ≠ mitochondrial secretion delivering peptide to local tissue. Biodistribution is completely unknown.
• ACS biomarker paradox (2025): PMID 41368821 shows MOTS-c is ELEVATED in acute coronary syndrome and predicts adverse events. Combined with the obesity paradox (PMID 41551324), this means MOTS-c goes UP in two major disease states. The simple "more = better" supplementation logic is increasingly untenable.
• Grey-market quality crisis: 30% incorrect amino acid sequences and 65% endotoxin contamination in internet-purchased peptides. Some community "non-responders" may simply be injecting the wrong peptide.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Research peptide suppliers present speculative dosing protocols as established science. "Research only" disclaimers serve as legal shields while marketing pages describe therapeutic protocols. No proprietary blends or "clinical strength" claims — MOTS-c is sold as raw peptide.
• Influencer economics: Jay Campbell dominates the MOTS-c protocol conversation (books, coaching, content). Dr. William Seeds provides clinical legitimacy through training programs. Ben Greenfield includes MOTS-c in personal stack content. None are MLM; all have commercial interests that benefit from MOTS-c adoption. Peter Attia discusses mechanism without personal endorsement.
• Counter-narrative manipulation: No pharma fearmongering detected — MOTS-c is too obscure. The strongest counter-narrative is from USADA/WADA (prohibition creates mystique that paradoxically increases interest among biohackers). CNN investigative report (Nov 2025) framed peptide ecosystem broadly but didn't target MOTS-c specifically.
• Content-farm explosion (2026): 6+ new SEO peptide sites launched since last review, all producing AI-generated content with vendor affiliate links. TikTok has emerged as a new platform. The information ecosystem is degrading faster than quality research can correct it.
• Cui bono summary: Who wins if you take it: peptide suppliers ($140-250/vial), compounding pharmacies (if Cat 1 passes), longevity influencers (engagement). Who wins if you don't: nobody specifically profits from you NOT taking MOTS-c. No competing product. This suggests genuine pre-commercial status, not suppression.
• Red team highlight (most concerning angle from 10-angle analysis): Second-order effects — if exogenous MOTS-c downregulates endogenous production, you create dependency on a research chemical with no guaranteed supply chain. This is unstudied and could create a iatrogenic problem worse than the original condition.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 4/10 — genuinely interesting mitochondrial-derived peptide with expanding preclinical applications (CK2 binding, insulin sensitivity, exercise mimetic) but minimal human outcome data; exercise already activates the same pathway with broader validation, and injectable format plus grey-market quality risk limit practical utility.
• Opportunity cost: Research-grade pricing has dropped to $18-56/month (2026, dose-dependent) from $210-750/month (2024) due to Chinese supply chain expansion. Financial barrier is lower, but quality risk is higher (30% incorrect sequences in grey-market). Adding an injectable still increases complexity (cold chain, sterile technique, monitoring). Mental bandwidth cost of tracking an N=1 experiment.
• Verdict: WATCH LIST — Revisit when NCT07505745 reports results (~2028). The biology is genuinely interesting (CK2 binding, nuclear translocation, expanding disease applications) but the evidence gap is too wide for self-experimentation when exercise already activates the same pathway.
• Conditions for upgrade to ADD: (1) Published Phase 2 results showing clinically meaningful insulin sensitivity improvement in NCT07505745; OR (2) at least one additional human dosing trial showing endpoint benefit; OR (3) specific lab markers showing MOTS-c deficiency that exercise doesn't correct (pending assay standardization).

Bottom Line

MOTS-c is a genuinely interesting mitochondrial-derived peptide with compelling animal biology: consistent AMPK-mediated metabolic improvements, impressive late-life anti-aging effects in mice, replicated cardiac protection, and rapidly expanding disease applications (now including AMD, OA, autism models, sleep apnea, disc degeneration, neonatal BPD). The CK2 direct binding discovery (2024) and nuclear translocation mechanism are scientifically significant. Research output has tripled in 2024-2026. The landmark NCT07505745 trial (Hudson Biotech, Phase 2a, N=120) is the first-ever human interventional study of native MOTS-c — a material upgrade from "zero human trials" to "first trial recruiting."

However, no human has received exogenous MOTS-c in a completed published study. Every dosing protocol remains extrapolation from mouse IP injection. The obesity paradox challenges the simple "deficiency replacement" rationale. If you are considering using this compound before NCT07505745 reports (~2028), you are conducting an N=1 experiment with a research chemical that has no human safety or efficacy data. Exercise, which reliably increases endogenous MOTS-c by 40%, remains the evidence-based intervention. Watch this space — MOTS-c is closer to human validation than it has ever been.

Practical Notes

Reconstitution: Add bacteriostatic water slowly down vial side. Swirl gently, don't shake. Typical concentration 1-2 mg/mL. Most stable at pH 5.0-7.0. Use within 2-4 weeks refrigerated (bac water) or 3-5 days (sterile water). MOTS-c degrades ~25% in 24h at room temp — reconstitute and refrigerate immediately.

Storage: Lyophilized: freezer (-20 to -80C) up to 24 months, with desiccant. Reconstituted: fridge (2-8C) only. Protect from light. Avoid freeze-thaw cycles. Glass vials preferred over plastic.

Injection technique: Insulin syringe (27-31 gauge), subcutaneous at 45-90 degrees. Rotate sites (abdomen, thigh, upper arm). Volume <=1 mL per site. Alcohol swab vial top each draw. Never reuse needles. Expect notable injection site burning (community-reported as worse than other peptides — likely mast cell activation).

Cost (updated 2026): Research vendor pricing has dropped: $25-37.50/vial (10mg promotional-standard), $175/vial (40mg). At 5mg daily: $37-56/month (research grade). At community-popular 3mg 3x/week: ~$18-27/month. Compounding pharmacy pricing (if Category 1 passes): significantly higher. Previous pricing ($140-250/10mg) was from 2024-early 2025; Chinese supply chain expansion has driven prices down sharply (U.S. peptide imports from China nearly doubled in 2025).

Regulatory: Not FDA approved. WADA prohibited under S4.4.1 (Metabolic Modulators — AMPK activators), not S2 (Peptide Hormones) — athletes subject to WADA testing must not use; no TUE available (no approved therapeutic use). FDA placed MOTS-c on 503A Category 2 list (Sept 2024) — compounding pharmacies prohibited from compounding for human use. Category 1 reclassification announced Feb 27, 2026 (Kennedy HHS) but not formally published — legal prohibition persists until Federal Register publication. No DEA scheduling. Available from research peptide suppliers (grey-market). Chinese supply chain expansion has driven prices down but quality concerns are acute.

What We Don't Know

• Whether NCT07505745 will show clinically meaningful insulin sensitivity improvement (results ~2028)
• Optimal dose for ANY human condition (first dose-finding data from NCT07505745)
• Human pharmacokinetics (ADME — completely uncharacterized)
• Whether SubQ administration achieves equivalent tissue exposure to IP injection
• Long-term safety in humans (months to years)
• Whether exogenous MOTS-c downregulates endogenous production
• Immunogenicity — will antibodies form? (NCT07505745 includes this endpoint)
• Individual variability in response (K14Q variant effects in humans)
• Whether the impressive mouse data translates to humans at all
• Cancer risk with chronic AMPK activation
• Interactions with any medication (zero drug interaction studies)
• Whether the compound adds benefit beyond exercise alone
• Whether the obesity MOTS-c paradox (PMID: 41551324) invalidates the "deficiency replacement" rationale
• Why injection site pain is so prominent (mast cell activation? formulation issue?) — community reports suggest desensitization over time
• Whether the community-reported palpitations represent a real cardiac signal
• Whether MOTS-c elevation in ACS (PMID: 41368821) means supplementation is harmful in cardiovascular disease
• Whether nasal spray formulations achieve any meaningful bioavailability
• Whether the 2026 dose de-escalation trend (1-3 mg vs 5-10 mg) reflects a genuine signal about optimal dosing
• Quality of grey-market peptides (30% incorrect sequences, 65% endotoxin contamination in studies)

References

Systematic Reviews & Meta-Analyses

1. Zhou Q et al. (2024). The correlation between MDP and metabolic states: systematic review and meta-analysis. Diabetol Metab Syndr 16:200. PMID: 39160573. Finding: MOTS-c reduced in T2DM (SMD -0.89) but increased in obesity (SMD +0.51).

Primary Research (Discovery & Mechanism)

2. Lee C et al. (2015). MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 21(3):443-454. PMID: 25738459. Discovery paper.
3. Kim KH et al. (2018). MOTS-c translocates to nucleus to regulate gene expression in response to metabolic stress. Cell Metabolism 28(3):516-524.e7. PMID: 29983246. Nuclear translocation mechanism.
4. Reynolds JC et al. (2021). MOTS-c is an exercise-induced regulator of age-dependent physical decline. Nature Communications 12(1):470. PMID: 33473109. Late-life anti-aging in mice.
5. Kumagai H et al. (2024). MOTS-c modulates skeletal muscle by directly binding CK2. iScience 27(11):111212. PMID: 39559755. First molecular target.
6. Gudiksen A et al. (2026). MOTS-c improves muscle mitochondrial bioenergetics via PGC-1alpha/AMPK. Free Radic Biol Med. PMID: 41520850.

Metabolic Disease & Insulin Resistance

7. Yin Y et al. (2022). MOTS-c relieves hyperglycemia in gestational diabetes. Pharmacol Res 175:105987. PMID: 34798268.
8. Yang B et al. (2021). MOTS-c + exercise synergy on insulin resistance via AMPK. BBA Mol Basis Dis 1867(6):166126. PMID: 33722744.
9. Cataldo LR et al. (2018). Plasma MOTS-c associated with insulin sensitivity in lean individuals. J Investig Med 66(6):1019-1022. PMID: 29593067.
10. Du C et al. (2018). Circulating MOTS-c decreased in obese male children. Pediatr Diabetes. PMID: 29691953.
11. Yoon SH et al. (2026). Systemic MOTS-c increased in obesity, unchanged after weight loss. J Clin Transl Endocrinol. PMID: 41551324. Obesity paradox.
12. Ozkaya DY et al. (2025). MOTS-c in obesity with inflammation, IR, endothelial dysfunction. Arch Endocrinol Metab. PMID: 41004666.

Exercise & Physical Performance

13. von Walden F et al. (2021). Acute endurance exercise stimulates circulating MOTS-c in humans. J Appl Physiol 131(3):1035-1042. PMID: 34351816.
14. Dieli-Conwright CM et al. (2021). Exercise effect on MOTS-c in breast cancer survivors. Sci Rep 11(1):16916. PMID: 34413391.
15. Yoon TK et al. (2022). Exercise, mitohormesis, and MOTS-c. Diabetes Metab J 46(3):402-413. PMID: 35656563.
16. Feng Y et al. (2025). Endurance training enhances skeletal muscle mito respiration via MOTS-c secretion. Free Radic Biol Med. PMID: 39706498.
17. Elhusseiny R et al. (2025). Heat stress modulates MOTS-c in active men during immobilization. Med Sci Sports Exerc. PMID: 40674654.

Cardiovascular & Cardiac Protection

18. Zhong P et al. (2022). MOTS-c prevents heart failure under pressure overload. J Cell Mol Med 26(21):5369-5378. PMID: 36156853.
19. Fu Y et al. (2024). MOTS-c regulates ROS/TXNIP/NLRP3 in diabetic cardiomyopathy. BBRC 741:151072. PMID: 39616938.
20. Wu N et al. (2023). MOTS-c attenuated diabetic cardiomyopathy in T1D mice. Cardiovasc Drugs Ther 39(3):491-498. PMID: 38141139.
21. Yuan J et al. (2023). MOTS-c + aerobic exercise cardiac adaptation via NRG1/ErbB4. Life Sciences 315:121330. PMID: 36584915.
22. Li Z et al. (2026). MOTS-c + exercise attenuate diabetic myocardial fibrosis via THBS1/TGF-beta. Front Endocrinol. PMID: 41710402.
23. Feng Z et al. (2026). MOTS-c attenuates cardiac dysfunction at high altitude via mitophagy. Free Radic Biol Med. PMID: 41654147.
24. Santhanam SS et al. (2026). Exogenous MOTS-c mitigates myocardial I/R injury. Naunyn Schmiedebergs Arch Pharmacol. PMID: 41593376.
25. Pham T et al. (2025). MOTS-c restores mito respiration in T2D heart. Front Physiol. PMID: 40661667.
26. Asil et al. (2024). SGLT2i effects on MOTS-c in diabetic HF patients. Eur J Pharmacol. PMID: 39182552.

Muscle Atrophy & Sarcopenia

27. Kumagai H et al. (2021). MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab 320(4):E680-E690. PMID: 33554779.
28. Elhusseiny R et al. (2026). MOTS-c + humanin attenuate dexamethasone muscle atrophy in human cells. Physiol Rep. PMID: 41732124.

Anti-Inflammatory, Antioxidant & Pulmonary

29. Zhang Y et al. (2024). MOTS-c alleviates radiation pneumonitis via Nrf2. Antioxidants 13(5):613. PMID: 38790718.
30. Li X et al. (2025). MOTS-c attenuates lung I-R injury via MYH9-dependent nuclear translocation. Redox Biology 84:103681. PMID: 40403491.
31. Chen D et al. (2026). MOTS-c alleviates bronchopulmonary dysplasia in neonatal mice via Nrf2. Eur J Pharmacol. PMID: 41802484.
32. Wen Z et al. (2024). FPR2/ferroptosis in ALI, MOTS-c protective. Int Immunopharmacol. PMID: 38527401.

Liver Protection

33. Lu et al. (2024). MOTS-c interacts with Bcl-2 in NASH. Cell Rep. PMID: 38206815.
34. Li N et al. (2026). MOTS-c protects against acetaminophen liver injury via MAPK. Protein Pept Lett. PMID: 41764620.
35. Chen F et al. (2025). MOTS-c mimics exercise to combat diabetic liver fibrosis via Keap1-Nrf2-Smad2/3. Sci Rep. PMID: 40425777.

Neuroprotection & Neurodevelopment

36. Bai Y et al. (2025). MOTS-c protects against LPS-sepsis brain injury via BBB. Int J Neurosci. PMID: 40753494.
37. Güvenir Seven S et al. (2026). MOTS-c therapeutic in VPA-induced autism model via BH4/BDNF. Mol Neurobiol. PMID: 41706383.
38. Rodríguez-Esparragón F et al. (2025). Humanin/MOTS-c biomarker + telomere in Alzheimer's. Int J Mol Sci. PMID: 41303353.

New Disease Models (2024-2026)

39. Li K et al. (2025). MOTS-c attenuates OA pyroptosis/cartilage degradation via Nrf2. Free Radic Biol Med. PMID: 41043625.
40. Mohtashami Z et al. (2025). MOTS-c therapeutic potential in AMD (patient-derived cybrids). Hum Cell. PMID: 39961901.
41. Luo Z et al. (2025). Reduced serum MOTS-c in obstructive sleep apnea. Sleep Biol Rhythms. PMID: 40538389.
42. Lin Y et al. (2025). MOTS-c-modified hydrogels for disc degeneration. Mater Today Bio. PMID: 40510834.
43. Yang L et al. (2024). MOTS-c for cancer-induced bone pain via AMPK. Acta Biochim Biophys Sin. PMID: 38716540.
44. Chen D et al. (2026). MOTS-c protects against placental injury in IUGR via Nrf2. Int J Mol Med. PMID: 41268602.

Reproductive & Endocrine

45. Liu S et al. (2026). MOTS-c targets SLC7A11 in spermatogenesis/ferroptosis. Free Radic Biol Med. PMID: 41933740.
46. Filibeli BE et al. (2026). Serum MOTS-c and m.1382A>C polymorphism in PCOS. Arch Endocrinol Metab. PMID: 41945630.
47. Kutuk IS et al. (2026). Reduced MOTS-c in PCOS with mitochondrial dysfunction. Sci Rep. PMID: 41680431.
48. Kong BS et al. (2025). MOTS-c prevents pancreatic islet cell senescence. Exp Mol Med. PMID: 40855115.
49. Blatkiewicz M et al. (2026). MOTS-c primes adrenal cortex metabolism. Folia Histochem Cytobiol. PMID: 41811086.

Cancer

50. Yin Y et al. (2024). MOTS-c suppresses ovarian cancer via USP7/LARS1. Adv Sci. PMID: 39321430.
51. Shen H et al. (2025). MOTS-c relieves HCC TRAIL resistance via MEF2A. Exp Cell Res. PMID: 39581216.

Other Mechanisms

52. Rice MC et al. (2024). MOTS-c as interferon-responsive host defense peptide. bioRxiv. PMID: 39553971.
53. Xu et al. (2024). MOTS-c treats diabetic neuropathy via AMPK/PGC-1alpha. Peptides. PMID: 38658141.
54. Shen Z et al. (2025). MOTS-c promotes glycolysis via AMPK-HIF-1alpha-PFKFB3 in CPB lung injury. Am J Respir Cell Mol Biol. PMID: 40035775.

Longevity & Genetic Polymorphisms

55. Fuku N et al. (2015). MOTS-c: a player in exceptional longevity? Aging Cell 14(6):921-923. PMID: 26289118.

Reviews

56. Zheng Y et al. (2023). MOTS-c: A promising MDP for therapeutic exploitation. Front Endocrinol 14:1120533. PMID: 36761202.
57. Mohtashami Z et al. (2022). MOTS-c in human aging and age-related diseases. Int J Mol Sci 23(19):11991. PMID: 36233287.
58. Wan W et al. (2023). MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med 21(1):36. PMID: 36670507.
59. Lee C et al. (2016). MOTS-c: regulating muscle and fat metabolism. Free Radic Biol Med 100:182-187. PMID: 27216708.
60. Gao Y et al. (2023). MOTS-c Functionally Prevents Metabolic Disorders. Metabolites 13(1):125. PMID: 36677050.
61. Mendias CL & Awan TM (2026). Safety and efficacy of peptide therapies. Sports Med. PMID: 41966639.
62. Fang T et al. (2025). MOTS-c in T2DM: from risk factors to cardiac complications. Life Sci 382:124009. PMID: 41083123.
63. Thoudam T et al. (2026). MDPs in liver disease. Hepatol Commun. PMID: 41543486.
64. Sivakumar R et al. (2026). MDPs as therapeutics for vascular aging and CVD. Curr Cardiol Rev. PMID: 40574402.

New Disease Models & Mechanisms (2024-2026 additions)

65. Zhang W et al. (2025). MOTS-c attenuates airway barrier dysfunction in allergic asthma by inhibiting epithelial apoptosis via Nrf2. Int Immunopharmacol. PMID: 40472776.
66. Cao P et al. (2025). Circulating MOTS-c as prognostic biomarker for MACE in acute MI. J Am Heart Assoc. PMID: 41368821.
67. Kim S (2024). K14Q polymorphism and sarcopenia, blood lipids, mental health in older Korean adults. Biomedicines. PMID: 39457696.
68. Coskun et al. (2024). MOTS-c levels in untreated preeclampsia. Mol Biol Rep. PMID: 39704971.
69. Iboleón-Jiménez A et al. (2025). Circulating mitochondrial biomarkers in acute coronary syndrome. Front Med. PMID: 40443515.
70. Wang J et al. (2024). MOTS-c + humanin ameliorate cyclophosphamide reproductive damage in male mice. Reprod Toxicol. PMID: 39079574.
71. Ozturk DA et al. (2024). Central MOTS-c infusion affects reproductive hormones in obese and non-obese rats. Neurosci Lett. PMID: 38462167.
72. Parseh S et al. (2024). Exercise intensity modulates MOTS-c in diabetic sand rats. Diabetes Res Clin Pract. PMID: 38636847.
73. Zou R et al. (2024). DNA-PKcs disrupts MOTS-c/JNK pathway in septic myocardial microvascular injury. Theranostics. PMID: 38389837.
74. Leciejewska N et al. (2025). MOTS-c impact on muscle cell differentiation across fiber types. Cell Physiol Biochem. PMID: 39876762.
75. Sidorenko DA et al. (2025). MOTS-c on soleus muscle in 7-day hindlimb suspension rats. J Muscle Res Cell Motil. PMID: 40608240.
76. Shu X et al. (2025). Avian MOTS-c characterization as metabolic regulator. Animals. PMID: 40805020.
77. Wang Z et al. (2024). MOTS-c attenuates inflammatory pain via central + peripheral mechanisms. Neurol Res. PMID: 37899006.
78. Bień J et al. (2025). MOTS-c modulates pancreatic islet function in rats and pigs in vitro. Histochem Cell Biol. PMID: 40478460.

Additional PMIDs cited in text

Sarcopenia/dialysis: 40005438. Hemodialysis CVD: 39111290. TRIM72 membrane repair: 39267782. HBV antiviral: 37788894. Bone metabolism review: 37200834. MI biomarker: 40353474. Metformin/breast cancer: 36490309. Adrenal tumors: 39201408. T1D kidney: 39711006. Multiple myeloma: 41479490. Aortic valve: 40104672. OSA cognition: 38704871. Radiation/cancer MOTS-c: 38314601. OSA editorial: 40538382. Pancreatic alpha/beta cells: 38430258. GLP-1/SGLT2i neurohumoral: 40008510. Nanocomposite sarcopenia: 41468174. CAR-T anticancer peptide: 41587709. Exercise muscle-fat crosstalk: 40872612. MDPs neurodegenerative: 40715951. MDPs Parkinson's: 40694987. MDPs CVD: 38008175, 40084698. MDPs antidiabetic: 38160808. Mitokines diabetic nephropathy: 37921178.